| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President & CEO
1 company
Travis C Mickle last filed a Form 4 in May 2022, as President & CEO at ZVRA. Travis C Mickle's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Travis C Mickle a below-average insider score of 37/100, based on 4 past trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -35.6%.
At the last filing, the largest reported position was 11,034 shares of ZVRA. Net of sales, the ZVRA filings show accumulation of 229,200 shares.
Travis C Mickle has 23 Form 4 filings on record from April 2015 to May 2022, all as President & CEO at Zevra Therapeutics (ZVRA), 2015–2022.
The 68 reported transactions were 27 open-market purchases, 16 gifts, 14 option or other derivative awards and 8 other transactions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 12 purchases worth about $319K and no sales.
The largest open-market purchase was 13,000 shares of ZVRA at an average $4.38 on May 25, 2022, about $57K. Twelve months later ZVRA was up 13%.
Shares as reported in the last Form 4 for each company; the most recent is from May 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 25, 2022 | ZVRA Zevra Therapeutics, Inc. | President & CEO | Buy | 13,000 | $4.38 | $56,996.00 | -661.2% | +26.0% | +12.9% | |
| Nov 18, 2021 | ZVRA Zevra Therapeutics, Inc. | President & CEO | Buy | 2,250 | $8.23 | $18,516.38 | +6.6% | -27.6% | -44.0% | |
| Aug 30, 2021 | ZVRA Zevra Therapeutics, Inc. | President & CEO | Buy | 5,000 | $8.92 | $44,607.50 | +17.1% | -11.8% | -39.8% | |
| Jun 14, 2021 | ZVRA Zevra Therapeutics, Inc. | President & CEO | Buy | 1,500 | $14.43 | $21,645.00 | +1.3% | -37.6% | -71.3% | |
| Jun 2, 2020 | ZVRA Zevra Therapeutics, Inc. | President & CEO | Buy | 110,000 | $0.19 | $20,790.00 | +6.2% | - | - | |
| Mar 5, 2020 | ZVRA Zevra Therapeutics, Inc. | President & CEO | Buy | 25,000 | $0.33 | $8,303.95 | +1.4% | - | - | |
| Sep 24, 2019 | ZVRA Zevra Therapeutics, Inc. | President & CEO | Buy | 50,000 | $0.79 | $39,381.50 | +2.9% | - | - | |
| Oct 12, 2018 | ZVRA Zevra Therapeutics, Inc. | President & CEO | Buy | 5,000 | $2.55 | $12,764.00 | +0.3% | - | - | |
| Jun 20, 2017 | ZVRA Zevra Therapeutics, Inc. | President & CEO | Buy | 8,000 | $3.45 | $27,592.00 | +88.4% | - | - | |
| Mar 22, 2017 | ZVRA Zevra Therapeutics, Inc. | President & CEO | Buy | 2,000 | $4.10 | $8,199.00 | +28.4% | - | - |